Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Biotech Receives $345 Million Go-Private Offer

publication date: Feb 1, 2016
Sinovac Biotech, a Beijing vaccine company, has received a privatization offer from management that values the company at $345 million. The offer is priced at $6.18 per share, a 23% premium to Sinovac's previous closing price of $5.02. Sinovac is the last of the US-listed China pharma companies to go private. After two years as private companies, other previously listed pharmas have been conducting new IPOs in Hong Kong, where their companies are given higher multiples and generate big rewards for the privatization investors. More details....

Stock Symbol: (NSDQ: SVA)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital